Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）
Status:
Unknown status
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and
development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and
tumor cell proliferation related kinase -c-Kit kinase. In the phase Ⅲ study, patients who
failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance
were treated with anlotinib or placebo, the anlotinib group PFS and OS were 5.37 months and
9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months. Therefore,we
envisage using anlotinib plus docetaxel treat the advanced non-small cell lung cancer after
the failure of Platinum-Based Doublet-Chemotherapy to further improve the patient's PFS or
OS.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Hospital of Qingdao University
Collaborators:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd